Eugia Pharma Receives USFDA Approval for Thiamine HCl Injection 200 mg/2 mL Multi-Dose Vials
Published: April 20, 2022
Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Thiamine HCl Injection 200 mg/2 mL Multi-Dose Vials.
Indications for this product include:
- Treatment of thiamine deficiency or beriberi.
- Also indicated in patients with established thiamine deficiency who cannot take thiamine orally.
Refer to package insert for full prescribing information.